Claims

[Claim 1] An anti-inflammatory pharmaceutical composition comprising (i) a crystalline form of the compound of Formula 1:



(1)

or a pharmaceutically acceptable salt thereof having a 50% volume particle diameter ($d_{(0.5)}$) of 3 μm to 9 μm, (ii) a pharmaceutically acceptable diluent, and (iii) a pharmaceutically acceptable lubricant.

[Claim 2] The anti-inflammatory pharmaceutical composition according to claim 1, wherein the compound of Formula 1 has a 90% volume particle diameter ($d_{(0.9)}$) of 10 μm to 100 μm.

[Claim 3] The anti-inflammatory pharmaceutical composition according to claim 1 or claim 2, wherein the compound of Formula 1 exists in crystalline form A that has the results of X-ray diffraction analysis shown in Table 1 and the differential scanning calorimetry (DSC) profile shown in Fig. 1:

TABLE 1

2θ	Intensity (cps)
8.40	7125
13.26	10050
14.02	2612
17.70	12200
18.48	10388
19.14	7400
19.84	5150
20.54	11750
22.72	2788
23.56	3100
27.62	3088

[Claim 4] The anti-inflammatory pharmaceutical composition according to any one of claim 1 to 3, wherein the compound of Formula 1 exists in crystalline form G that has the results of X-ray diffraction analysis shown in Table 2 and the differential scanning calorimetry (DSC) profile shown in Fig. 2:

TABLE 2

2θ	Intensity (cps)
11.10	3112
12.66	8762
16.92	7812
18.26	18038
19.48	8288
20.80	9775
22.46	4775
24.02	5350
25.42	17138
27.76	4700

[Claim 5] The anti-inflammatory pharmaceutical composition according to any one of claim 1 to 4, wherein the compound of Formula 1 exists in a mixture of the crystalline form A described in claim 2 and the crystalline form G described in claim 3.

[Claim 6] The anti-inflammatory pharmaceutical composition according to any one of claim 1 to 5, wherein the compound of Formula 1 comprises at least 50% by weight of the crystalline form A.

[Claim 7] The anti-inflammatory pharmaceutical composition according to any one of claim 1 to 6, wherein the diluent is selected from the group consisting of silicified microcrystalline cellulose, microcrystalline cellulose, cellulose, lactose, and combinations thereof.

[Claim 8] The anti-inflammatory pharmaceutical composition according to any one of claim 1 to 7, wherein the lubricant is talc or stearic acid.

[Claim 9] The anti-inflammatory pharmaceutical composition according to any one of claim 1 to 8, wherein the pharmaceutical composition comprises 0.5 to 20% by weight of the compound of Formula 1, 75 to 99% by weight of the diluent, and 0.1 to 5% by weight of the lubricant.

[Claim 10] The anti-inflammatory pharmaceutical composition according to any one of claim 1 to 9, wherein the pharmaceutical composition comprises 1% by weight of the compound of Formula 1, 98% by weight of the diluent, and 1% by weight of the lubricant.

[Claim 11] A capsule formulation comprising the pharmaceutical composition according to any one of claim 1 to 10.